Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
112 Results for "
SOS1
" in MedChemExpress (MCE) Product Catalog:
Products (112)
112 Results for "SOS1" in MCE Product Catalog:
Cat. No.: HY-175896
Research Areas:
SOS1 ligand-3 is a target protein ligand that can be used for the synthesis of PROTACs, such as BTX-6654 (HY-161233).
Cat. No.: HY-172221
SOS1-IN-18 (Compound 8) is the inhibitor for Son of Sevenless 1 protein (SOS1) with a KD of 2.6 nM, and inhibits SOS1-KRAS G12C interaction with an IC50 of 3.4 nM. SOS1-IN-18 inhibits the phosphorylation of ERK in H358 with an IC50 of 31 nM, inhibits the proliferation of H358 with an IC50 of 5 nM [1].
Cat. No.: HY-175326
CAS No.: 2767633-04-3
SOS1-IN-21 is an orally active inhibitor of son of Sevenless 1 (SOS1) with an IC50 of 15 nM. SOS1 is a guanine nucleotide exchange factor (GEF) that activates KRAS by facilitating the exchange of GDP for GTP. SOS1-IN-21 exhibits potent antiproliferative activity, with IC50 values of 16 nM in NCI-H358 and 17 nM in Mia Paca-2 cell proliferation assays. SOS1-IN-21 exhibits significant antitumor activity in the Mia Paca-2 xenograft model. SOS1-IN-21 can be used for the study of KRAS mutant tumors, such as pancreatic cancer [1].
Cat. No.: HY-168716
SOS1-IN-17 (Compound 8d) is an orally active inhibitor for SOS1-KRASG12C interaction with an IC50 of 5.1 nM. SOS1-IN-17 inhibits ERK phosphorylation in DLD-1 cell with an IC50 of 18 nM. SOS1-IN-17 exhibits anti-proliferative activity in KRASG12C mutated Mia-Paca-2 cell with an IC50 of 0.11 μM. SOS1-IN-17 exhibits antitumor efficacy against pancreatic cancer in mouse model [1].
Research Areas:
SOS1/EGFR-IN-1 (compound SE-9) is a dual-target inhibitor for the prostate cancer. SOS1/EGFR-IN-1 inhibits effectively SOS1(IC50=42.13±1.55 nM) and EGFR(IC50=1.01±0.04 nM) by inhibiting their downstream effector molecules. SOS1/EGFR-IN-1 induces apoptosis and G1 phase cell cycle arrest, reducing angiogenesis and migration. SOS1/EGFR-IN-1 shows significant antitumor effects in prostate cancer cells PC-3 (IC50=0.45±0.03 μM) [1].
Cat. No.: HY-19539
CAS No.: 909197-38-2
NSC-658497 is an effective inhibitor of Ras-GEF, SOS1. NSC-658497 binds to SOS1, competitively suppresses SOS1-Ras interaction, and dose-dependently inhibits SOS1 GEF activity. NSC-658497 showed dose-dependent efficacy in inhibiting Ras, downstream signaling activities, and associated cell proliferation [1].
Cat. No.: HY-176789
Research Areas:
VUBI1-octanoic acid is a conjugate of SOS1 ligand and linker, which can be used in the synthesis of (4S)-PROTAC SOS1 degrader-1 (HY-144657) [1].
Cat. No.: HY-161450
LHF418 is a SOS1 PROTAC degrader that induces the degradation of the target protein SOS1 by recruiting cereblon. LHF418 promotes the formation of the SOS1-PROTAC-CRBN ternary complex and induces SOS1 degradation in a cereblon- and proteasome-dependent manner. LHF418 inhibits EGF-induced ERK1/2 phosphorylation and the clonogenic growth of KRAS-mutant cancer cells. LHF418 can be used in studies related to SOS1-targeted protein degradation and KRAS-driven tumors [1].
Cat. No.: HY-122685
CAS No.: 116679-70-0
UC-773587 is a selective SOS1 catalytic activity inhibitor. UC-773587 binds to the catalytic site of Sos1 over HRas and ITSN (a RhoGEF) and inhibits nucleotide exchange with an IC50 value of 4.5 μM. UC-773587 mappes to the Ras switch II interaction region of the Sos1 catalytic site. UC-773587 can be used for the study of prostate cancer [1] .
Cat. No.: HY-184423
SOS1-IN-27 is a potent, selective allosteric SOS1 inhibitor with a KD of 14 nM and SOS1-KRAS binding IC50 of 1.6 nM. SOS1-IN-27 disrupts SOS1-KRAS interaction, inhibits MAPK/PI3K signaling, induces G1 arrest and tumor cell apoptosis. SOS1-IN-27 serves as a valuable tool compound for pan-KRAS-driven colorectal cancer studies [1].
Cat. No.: HY-184422
SOS1-IN-26 is a potent, orally active selective allosteric SOS1 inhibitor with a KD of 33 nM and SOS1-KRAS binding IC50 of 4.0 nM. SOS1-IN-26 disrupts SOS1-KRAS interaction, inhibits MAPK/PI3K signaling, induces G1 phase arrest and tumor cell apoptosis. SOS1-IN-26 serves as a balanced lead therapeutic candidate for pan-KRAS-driven colorectal cancer studies [1].
Cat. No.: HY-181807
SOS1/KRAS-IN-2 (Compound 20) is a SOS1::KRAS G12C protein-protein interaction inhibitor with a IC50 of 4.11 nM. SOS1/KRAS-IN-2 blocks the interaction between SOS1 and KRAS G12C. SOS1/KRAS-IN-2 induces cell Apoptosis. SOS1/KRAS-IN-2 exhibits anticancer activity against colorectal cancer and tongue squamous cell carcinoma [1].
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
